What’s new on emerging resistant Candida species
- 581 Downloads
Accounting for more than 400,000 annual cases worldwide, with an incidence from 0.24 to 34.3 patients/1000 ICU admissions and mortality that approaches 40%, Candida spp. constitute the third or fourth most common cause of healthcare-related infections worldwide . Although C. albicans remains the main causative pathogen, the increasing isolations of non-albicans Candida spp. resistant to first- and second-line antifungals (namely, fluconazole and echinocandins) in nosocomial infections is concerning. Resistance to azoles remains uncommon in C. albicans (< 5%), but it is more prevalent in C. glabrata (4–16%), C. parapsilosis (4–10%), and C. tropicalis (4–9%) . Acquired resistance following echinocandin exposure appears to be on the rise, and the emergence of multi-resistant species among Candida glabrata and the novel pathogen Candida auris poses a serious threat to critically ill patients.
Echinocandin-resistant Candida glabrata
Variable rates of acquired echinocandin...
Compliance with ethical standards
Conflicts of interest
The authors declare no conflict of interest.
- 3.Alexander BD, Johnson MD, Pfeiffer CD et al (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724–1732. https://doi.org/10.1093/cid/cit136 CrossRefGoogle Scholar
- 8.Delliere S, Healey K, Gits-Muselli M et al (2016) Fluconazole and echinocandin resistance of candida glabrata correlates better with antifungal drug exposure rather than with MSH2 mutator genotype in a french cohort of patients harboring low rates of resistance. Front Microbiol 7:2038. https://doi.org/10.3389/fmicb.2016.02038 CrossRefGoogle Scholar
- 16.Kohlenberg A, Struelens MJ, Monnet DL, Plachouras D (2018) Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. Euro Surveill. https://doi.org/10.2807/1560-7917.ES.2018.23.13.18-00136 Google Scholar
- 18.https://www.cdc.gov/fungal/diseases/candidiasis/tracking-c-auris.html. Accessed 6 May 2018
- 22.Chowdhary A, Prakash A, Sharma C et al (2018) A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–2017) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother 73:891–899. https://doi.org/10.1093/jac/dkx480 CrossRefGoogle Scholar
- 23.Hager CL, Larkin EL, Long LA, Ghannoum MA (2018) Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother 73:2085–2088. https://doi.org/10.1093/jac/dky153 CrossRefGoogle Scholar